The positive rates of these tumour markers in both groups were lower than previously reported positive rates of tumour markers in GC patients with CEA (21.8%), AFP (5.0%), CA19-9 (24.4%), and their combinations (47.1%, including CA125) [26], which indicated that the traditional markers are unsuitable for the prediction of the risk of GC in patients with EGC and PLGC. Here, CEACAM5 is linked to neoplasm.